1A-116 is primarily utilized in the field of cancer research due to its role as a potent inhibitor of the protein PARP-1 (Poly [ADP-ribose] polymerase 1). This enzyme is involved in DNA repair processes, and its inhibition can lead to the accumulation of DNA damage in cancer cells, particularly those with deficiencies in homologous recombination repair, such as BRCA-mutated cancers. By targeting PARP-1, 1A-116 enhances the effectiveness of chemotherapy and radiation therapy, making it a promising candidate for combination treatments in oncology. Additionally, its application extends to studying the mechanisms of DNA repair and cellular responses to genotoxic stress, providing valuable insights for developing novel therapeutic strategies.